Mizuho starts coverage on Tempus AI with Outperform rating and $100 price target. Leader in AI-powered precision oncology in a $40B market growing 30% annually—growth undervalued today.
Nancy Pelosi disclosed major stock transactions in January 2026, including exercising options on Amazon, Google, and Nvidia while selling Apple shares worth millions.
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
Tempus AI achieved its 10-year profitability target in Q3 2025, driven by massive 84.7% revenue growth and exceptional performance in its genomics and clinical testing divisions.
Canaccord initiates Tempus AI with Buy rating and $110 target, citing strong growth potential from AI-powered oncology testing and genomic profiling services.
Tempus AI and Whitehawk Therapeutics announce multi-year collaboration using AI and real-world data to develop targeted antibody drug conjugate therapies for cancer patients.
